Results 111 to 120 of about 67,365 (299)

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Review for "Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis"

, 2019

openalex   +1 more source

Review for "Number needed to treat in cardiovascular outcome trials with glucagon‐like peptide‐1 receptor agonists: A systematic review with temporal analysis"

, 2020
Salvatore Carbone
openalex   +1 more source

The Effects of Glucagon-Like Peptide-1 Receptor Agonists of Liraglutide on Bone Turnover Makers Among Type 2 Diabetes Mellitus Patients: A Meta-Analysis of Randomized Controlled Trials

, 2022
Jing-yi Kang, Shanshan Lei, Jintao Guan
openalex   +1 more source

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Nature Communications
Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy ...
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman   +11 more
doaj   +1 more source

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice

, 2007
Desu Chen, Jiayu Liao, Na Li, Caihong Zhou, Qing Liu, Guangxing Wang, Rui Zhang, Song Zhang, Lilin Lin, Kaixian Chen, Xin Xie, Fajun Nan, Andrew A. Young, Ming‐Wei Wang   +13 more
openalex   +2 more sources

Detection of a Small Insulinoma Using a Novel Glucagon-Like Peptide-1 Receptor Ligand [PDF]

, 2015
Sara K. Meibom
openalex   +1 more source

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source

Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Atrial Fibrillation Adverse Events: A Systematic Review and Meta-Analysis of Randomized Trials [PDF]

Henry O Aiwuyo, Irikefe P. Obiebi, Osagioduwa Mike Atoe-Imagbe, Uyilawa Okhuaihesuyi, John O Osarenkhoe, Anthony G Kweki, Christopher O Iruolagbe, Isa O Oboirien, Oluwasegun Matthew Akinti, Emmanuel Chinonso Okakpu, Ogie Derick Aghimien, Ovie Okorare, Jamal C Perry, Donald Tchapmi   +13 more
openalex   +1 more source

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight [PDF]

, 2014
Laurie L. Baggio, Daniel J. Drucker
openalex   +1 more source